← Back to headlines
Wells Fargo upgrades Ultragenyx Pharma stock on clinical data
Wells Fargo analysts raised their price target for Ultragenyx Pharmaceutical following positive Phase 3 trial results, citing improved therapeutic outcomes and commercial potential.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
